Fig. 3From: Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programCorrelation between change in systolic blood pressure and body weight at Week 40/42. Data taken from the safety population of SURPASS 1–5 pooled. SBP systolic blood pressure, r correlation coefficient, TZP tirzepatideBack to article page